BeOne Medicines Ltd.
BEIGFDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
How BEIGF's past catalysts played out
Sonrotoclax
Waldenstrom Macroglobulinemia
Zanubrutinib
Chronic Lymphocytic Leukemia
BGB-16673
B-cell Malignancy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sonrotoclax | Phase 3 | Waldenstrom Macroglobulinemia | - | - |
Zanubrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
BGB-16673 | Phase 2 | B-cell Malignancy | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BeOne Medicines Ltd.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in BeOne Medicines Ltd.'s (BEIGF) pipeline across Phase 3, Phase 2. Its lead program is Sonrotoclax (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BeOne Medicines Ltd.'s next FDA catalyst?→
BeOne Medicines Ltd.'s (BEIGF) next tracked catalyst is a Phase 2 expected September 22, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BEIGF biotech catalysts?→
Add BEIGF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BeOne Medicines Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.